Article Details
Retrieved on: 2024-12-07 20:08:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Vermont's implementation of a 1.75% fee on pharmaceutical companies, including biotech firms like Novartis, Novo Nordisk, and BioMarin, to fund drug-related initiatives. Many companies, however, are delayed in fee payments.
Article found on: www.vnews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here